<DOC>
	<DOCNO>NCT00124111</DOCNO>
	<brief_summary>The purpose study assess relative dose intensity ( RDI ) intravenous ( IV ) CMF Day 1 8 schedule give every 28 day pegfilgrastim support subject stage I-III breast cancer .</brief_summary>
	<brief_title>A Study Cyclophosphamide/Methotrexate/5-Fluorouracil ( CMF ) With Pegfilgrastim Subjects With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm breast cancer Stage I , II III Candidate IV CMF chemotherapy ( every 4 week ) total 6 cycle Chemotherapy naïve ( prior treatment hormone therapy antiHER2 monoclonal antibody therapy permit long treatment stop prior enrollment study ) Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L Platelet count great equal 100 x 10^9/L Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Written inform consent study specific procedure AST and/or ALT great 1.5 x upper limit normal ( ULN ) concomitant alkaline phosphatase great 2.5 x ULN accord institutional standard Bilirubin great 2 x ULN accord institutional standard Inadequate renal function ( creatinine great 1.5 x ULN accord institutional standard ) Any premalignant myeloid condition malignancy myeloid characteristic ( e.g. , myelodysplastic syndrome , acute chronic myelogenous leukaemia ) History prior malignancy breast cancer exception curatively treat basal cell squamous cell carcinoma skin , situ cervical carcinoma , surgically cured malignancy Prior radiotherapy Scheduled concomitant radiotherapy ( e.g. , radiotherapy administration study ) Documented active infection time enrolment require use systemic anti infectives Documented positive test human immunodeficiency virus ( HIV ) infection Known hypersensitivity E coli derive product [ e.g. , Filgrastim ( Neupogen® ) , pegfilgrastim ( Neulasta® ) , HUMULIN® Insulin , LAsparaginase , HUMATROPE® Growth Hormone , INTRON A® ] Subject currently enrol 30 day pass since complete investigational device drug trial ( ) receive investigational agent ( ) placebo ( confirmation prior treatment must document ) Pregnant breastfeeding ( subject child bear potential ) Not use adequate contraception ( subject child bear potential ) Previous participation study Inability unwillingness comply protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>clinical trial</keyword>
	<keyword>pegfilgrastim</keyword>
	<keyword>haematopoietic growth factor</keyword>
	<keyword>neutropenia</keyword>
	<keyword>CMF</keyword>
	<keyword>Cancer</keyword>
</DOC>